BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 35622442)

  • 1. Steroid treatment in the management of destructive thyrotoxicosis induced by PD1 blockade.
    Brancatella A; Pierotti L; Viola N; Lupi I; Montanelli L; Cremolini C; Piaggi P; Chella A; Antonuzzo A; Sgrò D; Antonangeli L; Sardella C; Brogioni S; Marcocci C; Santini F; Latrofa F
    Eur Thyroid J; 2022 Aug; 11(4):. PubMed ID: 35622442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of Thyrotoxicosis Induced by PD1 or PD-L1 Blockade.
    Brancatella A; Lupi I; Montanelli L; Ricci D; Viola N; Sgrò D; Antonangeli L; Sardella C; Brogioni S; Piaggi P; Molinaro E; Bianchi F; Aragona M; Antonuzzo A; Sbrana A; Lucchesi M; Chella A; Falcone A; Del Prato S; Elisei R; Marcocci C; Caturegli P; Santini F; Latrofa F
    J Endocr Soc; 2021 Sep; 5(9):bvab093. PubMed ID: 34337277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-L1 Inhibitor-Induced Thyroiditis Is Associated with Better Overall Survival in Cancer Patients.
    Kotwal A; Kottschade L; Ryder M
    Thyroid; 2020 Feb; 30(2):177-184. PubMed ID: 31813343
    [No Abstract]   [Full Text] [Related]  

  • 4. Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment.
    Muir CA; Clifton-Bligh RJ; Long GV; Scolyer RA; Lo SN; Carlino MS; Tsang VHM; Menzies AM
    J Clin Endocrinol Metab; 2021 Aug; 106(9):e3704-e3713. PubMed ID: 33878162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction-based prompt levothyroxine replacement to prevent a hypothyroid state after immune-related adverse events involving the thyroid gland.
    Yamauchi I; Hakata T; Sugawa T; Kosugi D; Fujita H; Okamoto K; Ueda Y; Fujii T; Taura D; Harada N; Inagaki N
    Endocr J; 2023 Oct; 70(10):987-998. PubMed ID: 37574279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune checkpoint inhibitor-related thyroid dysfunction.
    Iwama S; Kobayashi T; Yasuda Y; Arima H
    Best Pract Res Clin Endocrinol Metab; 2022 May; 36(3):101660. PubMed ID: 35501263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thyroid dysfunction after immune checkpoint inhibitor treatment in a single-center Chinese cohort: a retrospective study.
    Wu L; Xu Y; Wang X; Cheng X; Zhang Y; Wang Y; Fan X; Zhao H; Liu H; Chai X; Zhang L; Wang M; Li N; Pan H; Lian X
    Endocrine; 2023 Jul; 81(1):123-133. PubMed ID: 36867366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low frequency of positive antithyroid antibodies is observed in patients with thyroid dysfunction related to immune check point inhibitors.
    Mazarico I; Capel I; Giménez-Palop O; Albert L; Berges I; Luchtenberg F; García Y; Fernández-Morales LA; De Pedro VJ; Caixàs A; Rigla M
    J Endocrinol Invest; 2019 Dec; 42(12):1443-1450. PubMed ID: 31093955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of Thyroid Dysfunction in PD-1 Blockade Is Stratified by the Pattern of TgAb and TPOAb Positivity at Baseline.
    Zhou X; Iwama S; Kobayashi T; Ando M; Arima H
    J Clin Endocrinol Metab; 2023 Sep; 108(10):e1056-e1062. PubMed ID: 37084392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Antithyroid Antibodies in Checkpoint Inhibitor-Associated Thyroid Immune-Related Adverse Events.
    Muir CA; Wood CCG; Clifton-Bligh RJ; Long GV; Scolyer RA; Carlino MS; Menzies AM; Tsang VHM
    J Clin Endocrinol Metab; 2022 Apr; 107(5):e1843-e1849. PubMed ID: 35104870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thyroid Immune-Related Adverse Events in Patients with Cancer Treated with anti-PD1/anti-CTLA4 Immune Checkpoint Inhibitor Combination: Clinical Course and Outcomes.
    Lui DTW; Lee CH; Tang V; Fong CHY; Lee ACH; Chiu JWY; Leung RCY; Kwok GGW; Li BCW; Cheung TT; Woo YC; Lam KSL; Yau T
    Endocr Pract; 2021 Sep; 27(9):886-893. PubMed ID: 33581327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune Checkpoint Inhibitor-induced Thyroid Dysfunction Is Associated with Higher Body Mass Index.
    Pollack R; Ashash A; Cahn A; Rottenberg Y; Stern H; Dresner-Pollak R
    J Clin Endocrinol Metab; 2020 Oct; 105(10):. PubMed ID: 32668461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune Related Adverse Events of the Thyroid - A Narrative Review.
    Muir CA; Tsang VHM; Menzies AM; Clifton-Bligh RJ
    Front Endocrinol (Lausanne); 2022; 13():886930. PubMed ID: 35692394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Features of Nivolumab-Induced Thyroiditis: A Case Series Study.
    Yamauchi I; Sakane Y; Fukuda Y; Fujii T; Taura D; Hirata M; Hirota K; Ueda Y; Kanai Y; Yamashita Y; Kondo E; Sone M; Yasoda A; Inagaki N
    Thyroid; 2017 Jul; 27(7):894-901. PubMed ID: 28537531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pulsed intravenous methylprednisolone combined with oral steroids as a treatment for poorly responsive type 2 amiodarone-induced thyrotoxicosis.
    Campi I; Perego GB; Ravogli A; Groppelli A; Parati G; Persani L; Fugazzola L
    Eur J Endocrinol; 2019 Nov; 181(5):519-524. PubMed ID: 31536966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Prospective Study to Evaluate the Possible Role of Cholecalciferol Supplementation on Autoimmunity in Hashimoto's Thyroiditis.
    Bhakat B; Pal J; Das S; Charaborty SK; SircarMedical NR; Kolkata ; RGKar ; NorthBengal ; Siliguri
    J Assoc Physicians India; 2023 Jan; 71(1):1. PubMed ID: 37116030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delayed-onset immune-related adverse events involving the thyroid gland by immune checkpoint inhibitors in combination with chemotherapy: a case report and retrospective cohort study.
    Ueba Y; Yamauchi I; Hakata T; Fujita H; Okamoto K; Ikeda K; Ueda Y; Fujii T; Taura D; Inagaki N
    Endocr J; 2023 Mar; 70(3):323-332. PubMed ID: 36464271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term outcome of thyroid function after amiodarone-induced thyrotoxicosis, as compared to subacute thyroiditis.
    Bogazzi F; Dell'Unto E; Tanda ML; Tomisti L; Cosci C; Aghini-Lombardi F; Sardella C; Pinchera A; Bartalena L; Martino E
    J Endocrinol Invest; 2006 Sep; 29(8):694-9. PubMed ID: 17033257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lenvatinib-induced thyroid abnormalities in unresectable hepatocellular carcinoma.
    Koizumi Y; Hirooka M; Hiraoka A; Ochi H; Tanaka T; Yukimoto A; Imai Y; Watanabe T; Yoshida O; Miyake T; Matsuura B; Michitaka K; Joko K; Abe M; Hiasa Y
    Endocr J; 2019 Sep; 66(9):787-792. PubMed ID: 31142692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune-Related Thyroiditis with Immune Checkpoint Inhibitors.
    Iyer PC; Cabanillas ME; Waguespack SG; Hu MI; Thosani S; Lavis VR; Busaidy NL; Subudhi SK; Diab A; Dadu R
    Thyroid; 2018 Oct; 28(10):1243-1251. PubMed ID: 30132401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.